Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results.
Journal: Neurology and therapy
Published: February 27, 2026
Long-term real-world effectiveness of carbidopa/levodopa enteral suspension after 36 months of treatment initiation in advanced Parkinson's disease in the US: final results from the PROviDE study.
Journal: Clinical parkinsonism & related disorders
Published: February 23, 2026
Foslevodopa/Foscarbidopa Subcutaneous Infusion Safety and Efficacy in Patients with and Without Prior Deep Brain Stimulation.
Journal: Advances in therapy
Published: December 26, 2025
Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials.
Journal: Neurology and therapy
Published: June 13, 2025
Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease.
Journal: Movement disorders clinical practice
Published: April 07, 2025
Patients' experience with and perspectives on long-term use of continuous subcutaneous infusion of foslevodopa/foscarbidopa in Parkinson's disease.
Journal: Journal of neurology
Published: January 21, 2025
Sustained Therapeutic Benefits Using Image-Guided Programming at Activation of Deep Brain Stimulation for Parkinson's Disease.
Journal: Movement disorders clinical practice
Published: December 25, 2024
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.
Journal: Brain : a journal of neurology
Published: December 12, 2023
Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance.
Journal: Clinical parkinsonism & related disorders
Published: November 17, 2023
Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
Journal: Neurology and therapy
Published: October 10, 2023
Levodopa Carbidopa Intestinal Gel in Advanced Parkinson's Disease: DUOGLOBE Final 3-Year Results.
Journal: Journal of Parkinson's disease
Published: June 11, 2023
Last Updated: 09/26/2026